Table 2.
Characteristics | n | BRCA1/BRCA2 | BRCA1 | BRCA2 | |||||
---|---|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | p | Negative | Positive | p | ||
Age [mean (min-max)] | 46 (28-82) | 43.7 (27-63) | 45.7 | 45.5 | 0.781 | 46.0 | 41.4 | 0.190 | |
Germline mutation | 81 (81%) | 19 (19%) | 88 (88%) | 11 (11%) | 91 (91%) | 8 (8%) | |||
Family History | 21 | 17 (81%) | 4 (19%) | 19 (90.5%) | 2 (9.5%) | 1.000 | 19 (90.5%) | 2 (9. 5%) | 1.000 |
Bilateral breast carcinoma | 7 | 6 (86%) | 1 (14%) | 7 | 0 | 0.351 | 6 (86%) | 1 (14%) | 1.000 |
Breast + ovarian carcinoma | 7 | 4 (67.2%) | 3 (42.8%) | 5 (71.5%) | 2 (28.5%) | 0.173 | 6 (85.8%) | 1 (14.2%) | 0.456 |
Triple-negative tumor | 33 | 25 (75.7%) | 8 (24.2%) | 27 (81.8%) | 6 (18.1%) | 0.172 | 31 (93.9%) | 2 (6.0%) | 0.715 |
Below 40 years old | 41 | 33 (80.4%) | 8 (19.5%) | 37 (90.2%) | 4 (9.5%) | 1.000 | 37 (90.2%) | 4 (9.5%) | 0.715 |
Triple negative + below 40 years old | 8 | 5 (62.5%) | 3 (37.5%) | 6 (75%) | 2 (25%) | 7 (87.5%) | 1 (12.5%) | ||
ER Positive | 60 | 51 (85%) | 9 (15%) | 56 (93.3%) | 4 (6.6%) | 0.316 | 55 (91.6%) | 5 (8.33%) | 0.824 |
ER Negative | 39 | 29 (74.3%) | 10 (25%) | 32 (82%) | 7 (17.9%) | 36 (92.3%) | 3 (7.6%) | ||
PR Positive | 53 | 45 (84.9%) | 8 (15%) | 49 (92.4%) | 4 (7.5%) | 0.526 | 49 (92.4%) | 4 (7.5%) | 1.000 |
PR Negative | 46 | 35 (76%) | 11 (23.9%) | 39 (84.7%) | 7 (15.2%) | 42 (91.3%) | 4 (8.6%) | ||
HER 2 Positive | 10 | 10 (100%) | 0 | 10 (100%) | 0 | 0.650 | 10 (100%) | 0 | 1.000 |
Right Breast | 47 | 36 (76.5%) | 11 (23.4%) | 39 (82.9%) | 8 (17%) | 0.262 | 44 (93.6%) | 3 (6.3%) | 0.710 |
Left Breast | 45 | 37 (82.2%) | 8 (17.7%) | 42 (93.3%) | 3 (6.6%) | 40 (88.8%) | 5 (11.1%) | ||
Invasive Ductal Carcinoma | 86 | 69 (80%) | 17 (19%) | 75 (87%) | 11 (12%) | 0.351 | 80 (93%) | 6 (6.9%) | 0.245 |
Invasive Lobular Carcinoma | 10 | 9 (90%) | 1 (10%) | 10 | 0 | 0.596 | 9 (90%) | 1 (10%) | 0.583 |